File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1572-0241.2007.01715.x
- Scopus: eid_2-s2.0-41849094074
- PMID: 18177451
- WOS: WOS:000254665200009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome
Title | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome |
---|---|
Authors | |
Issue Date | 2008 |
Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html |
Citation | American Journal Of Gastroenterology, 2008, v. 103 n. 4, p. 865-871 How to Cite? |
Abstract | BACKGROUND: The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding. However, information in this area is scarce. AIM: This retrospective study aimed to determine the incidence of upper gastrointestinal bleeding in a real-life situation. The effect of proton pump inhibitor (PPI) treatment was also analyzed. METHOD: From January 2002 to December 2006, all patients receiving combination therapy were analyzed. The end point was the occurrence of upper gastrointestinal bleeding during combination therapy or within 7 days of stopping enoxaparin. RESULTS: The patient group consisted of 666 patients (age 72.1 ± 12.6 yr). Gastrointestinal bleeding occurred in 18 (2.7%) patients. The overall hospital mortality was 4.1% (27 patients). A cardiac event was the major cause (N = 24, 3.6%). Only one patient died of massive gastrointestinal bleeding (0.15%). Multiple logistic regression analysis demonstrated that previous peptic ulcer, cardiogenic shock, and the lack of PPI coprescription were significant risk factors for gastrointestinal bleeding. The age-adjusted odds ratio (95% confidence interval) for gastrointestinal bleeding was 5.07 (1.31-16.58) for previous peptic ulcer, 21.41 (2.56-146.68) for cardiogenic shock, and 0.068 (0.010-0.272) for the coprescription with a PPI. CONCLUSION: In real life, the incidence of gastrointestinal bleeding associated with the combination of aspirin, clopidogrel, and enoxaparin therapy was estimated to be 2.7%. Previous peptic ulcer disease or cardiogenic shock were significant independent risk factors. Coprescription with a PPI can significantly reduce the risk. © 2008 by Am. Coll. of Gastroenterology. |
Persistent Identifier | http://hdl.handle.net/10722/163158 |
ISSN | 2023 Impact Factor: 8.0 2023 SCImago Journal Rankings: 2.391 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ng, FH | en_US |
dc.contributor.author | Wong, SY | en_US |
dc.contributor.author | Lam, KF | en_US |
dc.contributor.author | Chang, CM | en_US |
dc.contributor.author | Lau, YK | en_US |
dc.contributor.author | Chu, WM | en_US |
dc.contributor.author | Wong, BCY | en_US |
dc.date.accessioned | 2012-09-05T05:28:16Z | - |
dc.date.available | 2012-09-05T05:28:16Z | - |
dc.date.issued | 2008 | en_US |
dc.identifier.citation | American Journal Of Gastroenterology, 2008, v. 103 n. 4, p. 865-871 | en_US |
dc.identifier.issn | 0002-9270 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163158 | - |
dc.description.abstract | BACKGROUND: The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding. However, information in this area is scarce. AIM: This retrospective study aimed to determine the incidence of upper gastrointestinal bleeding in a real-life situation. The effect of proton pump inhibitor (PPI) treatment was also analyzed. METHOD: From January 2002 to December 2006, all patients receiving combination therapy were analyzed. The end point was the occurrence of upper gastrointestinal bleeding during combination therapy or within 7 days of stopping enoxaparin. RESULTS: The patient group consisted of 666 patients (age 72.1 ± 12.6 yr). Gastrointestinal bleeding occurred in 18 (2.7%) patients. The overall hospital mortality was 4.1% (27 patients). A cardiac event was the major cause (N = 24, 3.6%). Only one patient died of massive gastrointestinal bleeding (0.15%). Multiple logistic regression analysis demonstrated that previous peptic ulcer, cardiogenic shock, and the lack of PPI coprescription were significant risk factors for gastrointestinal bleeding. The age-adjusted odds ratio (95% confidence interval) for gastrointestinal bleeding was 5.07 (1.31-16.58) for previous peptic ulcer, 21.41 (2.56-146.68) for cardiogenic shock, and 0.068 (0.010-0.272) for the coprescription with a PPI. CONCLUSION: In real life, the incidence of gastrointestinal bleeding associated with the combination of aspirin, clopidogrel, and enoxaparin therapy was estimated to be 2.7%. Previous peptic ulcer disease or cardiogenic shock were significant independent risk factors. Coprescription with a PPI can significantly reduce the risk. © 2008 by Am. Coll. of Gastroenterology. | en_US |
dc.language | eng | en_US |
dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html | en_US |
dc.relation.ispartof | American Journal of Gastroenterology | en_US |
dc.subject.mesh | Acute Coronary Syndrome - Drug Therapy | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 And Over | en_US |
dc.subject.mesh | Anticoagulants - Adverse Effects | en_US |
dc.subject.mesh | Aspirin - Adverse Effects | en_US |
dc.subject.mesh | Drug Therapy, Combination | en_US |
dc.subject.mesh | Enoxaparin - Adverse Effects | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gastrointestinal Hemorrhage - Chemically Induced | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Logistic Models | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Platelet Aggregation Inhibitors - Adverse Effects | en_US |
dc.subject.mesh | Retrospective Studies | en_US |
dc.subject.mesh | Statistics, Nonparametric | en_US |
dc.subject.mesh | Ticlopidine - Adverse Effects - Analogs & Derivatives | en_US |
dc.title | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lam, KF:hrntlkf@hkucc.hku.hk | en_US |
dc.identifier.email | Wong, BCY:bcywong@hku.hk | en_US |
dc.identifier.authority | Lam, KF=rp00718 | en_US |
dc.identifier.authority | Wong, BCY=rp00429 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1572-0241.2007.01715.x | en_US |
dc.identifier.pmid | 18177451 | en_US |
dc.identifier.scopus | eid_2-s2.0-41849094074 | en_US |
dc.identifier.hkuros | 147577 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-41849094074&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 103 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.spage | 865 | en_US |
dc.identifier.epage | 871 | en_US |
dc.identifier.isi | WOS:000254665200009 | - |
dc.publisher.place | United States | en_US |
dc.identifier.f1000 | 1108609 | - |
dc.identifier.scopusauthorid | Ng, FH=16936078000 | en_US |
dc.identifier.scopusauthorid | Wong, SY=7404590845 | en_US |
dc.identifier.scopusauthorid | Lam, KF=8948421200 | en_US |
dc.identifier.scopusauthorid | Chang, CM=20833817800 | en_US |
dc.identifier.scopusauthorid | Lau, YK=7201403303 | en_US |
dc.identifier.scopusauthorid | Chu, WM=23995209500 | en_US |
dc.identifier.scopusauthorid | Wong, BCY=7402023340 | en_US |
dc.identifier.citeulike | 2640574 | - |
dc.identifier.issnl | 0002-9270 | - |